Auxilium Pharmaceuticals — Investor Presentation (September 2008)
46 slides from Auxilium Pharmaceuticals's investor presentation, Sep 3, 2008
Slide 1: September 2008
Exhibit 99.1 September 2008
Slide 2: Safe Harbor Statement
Safe Harbor Statement Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to ma
Slide 3: Slide 3
Slide 4: Auxilium Pharmaceuticals, Inc.
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) • Specialty biopharmaceutical company focused on Urologists, Endocrinologists, Orthopedists and certain PCPs • Founded in 1999 • Headquarters in Malvern, Pa. – Manufacturing in Horsham, Pa. – Approximately 33
Slide 5: Broad Maturing Pipeline
Broad Maturing Pipeline Market Phase III Phase II Phase I Hypogonadism Dupuytren’s Contracture Peyronie’s Disease Frozen Shoulder Syndrome Overactive Bladder Pain Broad Maturing Pipeline Note: Worldwide rights for all products available, except Testim where ex -U.S. rights have been licensed. XIAFLE
Slide 6: Anticipated News Flow Events
Anticipated News Flow Events 5 Q409 Q309 Q209 Q109 2010 Anticipated News Flow Events Q308: • XIAFLEX - Initiate Peyronie's Phase IIb Study H109: • XIAFLEX - Open Label Safety Data Early 2009: • XIAFLEX - File BLA for Dupuytren's Contracture Early 2010 • XIAFLEX - FDA Approval In Dupuytren’s Contract
Slide 7: XIAFLEX: Unique, Late-Stage Opportunity with Blockbuster Potential
XIAFLEX™ (clostridial collagenase for injection) Unique, Late-Stage Opportunity with Blockbuster Potential
Slide 8: XIAFLEX- Unique, Late-Stage, Blockbuster Opportunity
XIAFLEX- Unique, Late-Stage, Blockbuster Opportunity XIAFLEX- Unique, Late-Stage, Blockbuster Opportunity • Potential to be first effective non-surgical treatment for two high unmet needs – Late-Stage Phase III data for the treatment of Dupuytren’s contracture -expect to file U.S. BLA in early 2009
Slide 9: Dupuytren's Contracture—a Debilitating Condition
Dupuytren’s Contracture—a Debilitating Condition Dupuytren’s Contracture—a Debilitating Condition • Excessive collagen deposition • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Debilitating effect on quality of life • Surgery may be reser
Slide 10: Current Treatment Options Are Invasive or Ineffective
Current Treatment Options Are Invasive or Ineffective Current Treatment Options Are Invasive or Ineffective • Surgery • Non-surgical options – Splinting – Physical therapy – Corticosteroids • Needle fasciotomy/ aponeurotomy • Amputation
Slide 11: Dupuytren's Contracture—Unmet Medical Need
Dupuytren’s Contracture—Unmet Medical Need Dupuytren’s Contracture—Unmet Medical Need • Disease prevalence is estimated at 3%-6% among adult Caucasians, but occurs in all populations • Higher prevalence in patients of northern-European descent • Hereditary component in approximately 40% of patients
Slide 12: XIAFLEX—Potential to Revolutionize Treatment for Dupuytren's Contracture
XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture
Slide 13: XIAFLEX—Potential to Revolutionize Treatment for Dupuytren's Contracture
XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture
Slide 14: Pivotal Phase III Study (DUPY-303): Results
Pivotal Phase III Study (DUPY-303): Results* 0/12 0/7 0/5 91% 86% 100% 85% 0% 0% 0% 0% 20% 40% 60% 80% 100% Pivotal Phase III Study (DUPY-303): Results* • 54/62 (87%) joints achieved 0°-5° contracture in the study and its open-label extension • Recurrence rates – 3 of 54 joints followed for 12 month
Slide 15: Most Patients Achieved Full Extension, Regardless of Joint Affected or Severity
Most Patients Achieved Full Extension, Regardless of Joint Affected or Severity Most Patients Achieved Full Extension, Regardless of Joint Affected or Severity 92% 78% 86% 61% 47% 53% 79% 60% 70% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% MP PIP Combined 10,000 units, approximately 0.58 mg. Joint T
Slide 16: CORD I Design
CORD I Design CORD I Design • Largest ever double-blind, placebo-controlled trial in Dupuytren’s Contracture – randomized in 2:1 ratio of active to placebo – enrolled a 2:1 ratio of MP:PIP – enrolled 1:1 ratio of less severe to more severe joints • Primary endpoint is reduction in contracture to wit
Slide 17: Primary Endpoint Outcome Compares Favorably To Surgery
Primary Endpoint Outcome Compares Favorably To Surgery Primary Endpoint Outcome Compares Favorably To Surgery
Slide 18: 4 Out Of 5 Dupuytren's Contracture Patients Improved By 50%
4 Out Of 5 Dupuytren’s Contracture Patients Improved By 50% 4 Out Of 5 Dupuytren’s Contracture Patients Improved By 50%
Slide 19: Contracture Reduction By Degrees Indicates Average XIAFLEX Patient Achieves ~10°
Contracture Reduction By Degrees Indicates Average XIAFLEX Patient Achieves ~10° Of Contracture Contracture Reduction By Degrees Indicates Average XIAFLEX Patient Achieves ~10° Of Contracture
Slide 20: XIAFLEX Phase III AE and SAE Rates Should Compare Favorably To Surgical Complications
XIAFLEX Phase III AE and SAE Rates Should Compare Favorably To Surgical Complications XIAFLEX Phase III AE and SAE Rates Should Compare Favorably To Surgical Complications Serious Adverse Events Number Rate/Inj. Tendon / Ligament*: Confirmed Tendon Rupture 0.14% Ligament Injury 0.05% Total Tendon /
Slide 21: CORD I Key Takeaways
CORD I Key Takeaways CORD I Key Takeaways • Primary endpoint of 5° reached in 64% of patients (p<0.001) – 25 of 26 endpoints met with statistical significance of <0.001, 1 of 26 was met with a p-value = 0.002 – Of the 73 patients who didn’t respond, 44 received less than 3 injections and 25 had no p
Slide 22: Dupuytren's Commercial Opportunity
Dupuytren’s Commercial Opportunity We believe: • There is a pent-up demand for non-surgical therapy • Surgeons and patients prefer non-invasive treatment • Each patient on average has 2.2 joints which will require treatment; about half have contractures in both hands • Early data indicates on averag
Slide 23: Market Research Performed – Dupuytren's
Market Research Performed – Dupuytren’s Market Research Performed – Dupuytren’s • Multiple prevalence data sets proved to be highly variable in numbers of patients • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Dupuytren’s contracture • A combined 571
Slide 24: At least 240,000 Dupuytren's Candidates In U.S. & Europe Annually
At least 240,000 Dupuytren’s Candidates In U.S. & Europe Annually Patients Seeking Treatment ~1,030,000 No Prior Surgery ~540,000 Had Surgery Previously ~490,000 Watchful Waiting ~270,000 Medical/ Surgical Treatment ~270,000 Medical/ Surgical Treatment ~125,000 Watchful Wait/ In Follow Up ~365,000 X
Slide 25: Expected Pathway to BLA Filing in Early 2009
Expected Pathway to BLA Filing in Early 2009 Expected Pathway to BLA Filing in Early 2009 • Complete 12 month open-label safety follow up from >100 CORD I patients originally randomized to XIAFLEX • Complete open-label CORD II and JOINT I/II trials to attain 1,000 patient exposure data • Finalize BL
Slide 26: XIAFLEX I.P. Position for Dupuytren's Contracture
XIAFLEX I.P. Position for Dupuytren’s Contracture XIAFLEX I.P. Position for Dupuytren’s Contracture • U.S. Orphan Drug Exclusivity granted on May 23, 1996 for 7 years post approval • Market Exclusivity expected in EU for 10 years post - approval –Data protection granted for 8 years • Method of Use P
Slide 27: Peyronie's Disease—a Devastating Disorder
Peyronie’s Disease—a Devastating Disorder 1. Smith BH. Am J Clin Pathol . 1966;45:670-678. 2. Somers KD, Dawson DM. J Urol . 1997;157:311-315. Peyronie’s Disease—a Devastating Disorder • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Sympt
Slide 28: Epidemiology—Peyronie's Disease
Epidemiology—Peyronie’s Disease • Prevalence of Peyronie’s disease is estimated at 1 in 20 adult men – Actual prevalence higher based on autopsies • Prevalence rate increases with age – The average age of disease onset is years • High association with other diseases such as: – Diabetes, erectile dys
Slide 29: Current Treatment—Surgical
Current Treatment—Surgical Current Treatment—Surgical • The goal of surgery is simply to make the two sides of the penis equal in size • Graft or prosthetic may be required • Cost of surgery in U.S. is ~$10-12K
Slide 30: Peyronie's Disease—Unapproved Treatments Have Been Used With Little Reported Success
Peyronie’s Disease—Unapproved Treatments Have Been Used With Little Reported Success Peyronie’s Disease—Unapproved Treatments Have Been Used With Little Reported Success • Verapamil • Vitamin E • Colchicine • Potassium aminobenzoate (Potaba) • Tamoxifen • Interferon alpha-2a • Corticosteroids • Ener
Slide 31: Promising Phase II Results: Patients With 25% Reduction in the Angle of Deviation
Promising Phase II Results: Patients With 25% Reduction in the Angle of Deviation Promising Phase II Results: Patients With 25% Reduction in the Angle of Deviation Study 1030 58% 53% 35% 0% 20% 40% 60% 80% 100% Month 3 Month 6 Month 9 Study 1035 50% 100% 100% 89% 0% 20% 40% 60% 80% 100% Week 6 Month
Slide 32: Market Research Performed – Peyronie's
Market Research Performed – Peyronie’s Market Research Performed – Peyronie’s • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Peyronie’s disease • A combined 575 Urologists have been interviewed to estimate market size (415 in U.S.; 160 in Europe) and
Slide 33: At least 210,000 Peyronie's Candidates In U.S. and Europe Annually
At least 210,000 Peyronie’s Candidates In U.S. and Europe Annually Patients Seeking Treatment ~475,000 Surgery Not Recommended ~365,000 Watchful Waiting ~160,000 Medical or Intralesional Therapy ~205,000 Surgery Recommended ~110,000 XIAFLEX Potential Candidates or 67% of Medical/ Surgical candidates
Slide 34: Peyronie's Clinical Plan
Peyronie’s Clinical Plan Peyronie’s Clinical Plan • Phase IIb dose ranging study expected to begin in Q3 2008 • A proprietary Patient Reported Outcome (PRO) questionnaire has been developed – To be validated in Phase IIb and likely to be used as a primary efficacy endpoint in Phase III clinical tria
Slide 35: XIAFLEX I.P. Position for Peyronie's Disease
XIAFLEX I.P. Position for Peyronie’s Disease XIAFLEX I.P. Position for Peyronie’s Disease • U.S. Orphan Drug Exclusivity granted on March 12, 1996 for 7 years post approval • Market Exclusivity in EU could be extended to 11 years on approval of additional indication –Biosimilars would need to genera
Slide 36: Testim 1% Testosterone Gel: Near-Term Growth Driver
Testim ® 1% Testosterone Gel: Near-Term Growth Driver Executing on Opportunities
Slide 37: Testim is the Fastest Growing Testosterone Replacement Therapy Gel
Testim ® is the Fastest Growing Testosterone Replacement Therapy Gel Testim ® is the Fastest Growing Testosterone Replacement Therapy Gel • Proprietary, topical 1% testosterone gel – Once-a-day application – Favorable clinical and commercial profile • Recent study indicates 39% of U.S. males over 45
Slide 38: Patient Benefits are Clinically Proven
Patient Benefits are Clinically Proven Total Testosterone Free Testosterone Patient Benefits are Clinically Proven 2,000 3,000 4,000 5,000 6,000 Mean AUC 0-24 (ng*h/dL) Testim AndroGel Mean AUC 0-24 (ng*h/dL) Testim AndroGel • clinical studies involving approx. 1,800 patients – largest placebo-contr
Slide 39: Gels Fastest Growing TRT Segment
Gels Fastest Growing TRT Segment Gels Fastest Growing TRT Segment Source: IMS data ($ in millions) Gel Patch Oral Injectables $35 $117 $200 $287 $340 $383 $449 $459 $399 $302 $210 $77 $59 $49 $499 $118 $568 Gel Segment Growth ($) Jun 2008 L12M: Gel Segment Growth ($) Gel Segment Growth ($) Jun 2008
Slide 40: Testim quarterly net revenues and scripts: Consistent Growth
Testim ® quarterly net revenues and scripts Established Track Record of Consistent Growth ® ($ in millions) Established Track Record of Consistent Growth Q2 2008 Net Revenues Y/Y Growth: Q2 2008 Net Q2 2008 Net Revenues Revenues Y/Y Growth: Y/Y Growth: Q2 2008 TRX YY Growth: Q2 2008 TRX Q2 2008 TRX
Slide 41: We Believe Testim Is Driving Growth in Overall Gel Market
We Believe Testim Is Driving Growth in Overall Gel Market Testim Share of TRx of Gel Market Source: IMS data 22.2% 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% Mar-03 July-08 Strong market share with high-prescribing urologists & PCP’s; 41.9% gel market share of decile 8-10 Urologists and 29.9% share with deci
Slide 42: Testim Patent Coverage
Testim Patent Coverage • U.S. Patent # 7,320,968 covering method of use claims for Testim issued January 22, 2008; expires 2025 • We believe no Paragraph III ANDA was filed prior to issuance of the ’968 patent, since five months have passed since listing in the Orange Book • Divisional application a
Slide 43: Financials / Strategic Priorities
Financials / Strategic Priorities
Slide 44: 2Q08 Financial Results and 2008 Guidance ($ Millions)
2Q08 Financial Results and 2008 Guidance ($ Millions) Q2 ’08 1H’08 Guidance Revenues $30.9 $58.0 $120-125 R&D Expense $13.4 $26.6 $52-56 SG&A Expense $22.2 $43.2 $88-92 Net Loss ($11.7) ($24.0) ($44- 48) Stock – Based Comp Expense $2.8 $4.9 $9-11 Cash & cash equivalents $48.8 2Q08 Financial Results
Slide 45: Strategic Priorities
Strategic Priorities Strategic Priorities • Continue Development of XIAFLEX with a plan to: – File Dupuytren’s BLA in early 2009 – Initiate Phase IIb in Peyronie’s Disease in Q3 2008 – Continue market research activities; prepare commercial team – Continue development of XIAFLEX in Peyronie’s Diseas
Slide 46: Slide 46
Auxilium Pharmaceuticals — Investor Presentation (September 2008) on 6ix